[Clinico-electroencephalographic evaluation of a new benzodiazepine (Ro 05-4023) by oral administration in epileptic patients by double blind technic].
D000284:Administration, Oral; D000293:Adolescent; D000927:Anticonvulsants; D001552:Benzazepines / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D004569:Electroencephalography; D004827:Epilepsy / Q000188:drug therapy*; D005069:Evaluation Studies as Topic; D005260:Female; D006429:Hemiplegia / Q000150:complications; D006801:Humans; D008607:Intellectual Disability / Q000150:complications; D007659:Ketones / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D009574:Nitro Compounds / Q000009:adverse effects / Q000627:therapeutic use
D000927:Anticonvulsants; D001552:Benzazepines; D007659:Ketones; D009574:Nitro Compounds
Ensayo de valoración clinicoelectroencefalográfica de un nuevo derivado benzodiazepínico (Ro 05-4023) por administración oral en pacientes epilépticos con técnica de doble ceguera.